Logo

Vertex Collaborates with Molecular Templates to Discover and Develop Conditioning Regimens Enhancing Hematopoietic Stem Cell Transplants

Share this

Vertex Collaborates with Molecular Templates to Discover and Develop Conditioning Regimens Enhancing Hematopoietic Stem Cell Transplants

Shots:

  • Molecular Templates (MTEM) to receive $38M up front including an equity investment- up to $522M as development- regulatory- commercial milestones- option payment for two targets and royalties on sales of products
  • MTEM will conduct research activities to discover a new conditioning regimen utilizing its engineered toxin body (ETB) platform for up to two targets selected by Vertex including CTX001. Additionally- Vertex will get an option to select a second target and to license selected molecules with an exclusive right to develop selected molecules for any indication
  • CTX001 is an ex vivo CRISPR/Cas9 gene editing therapy- currently being evaluated in two ongoing P-I/II studies in patients with transfusion-dependent beta thalassemia and severe sickle cell disease- where a hematopoietic stem cell transplant is required as part of treatment with CTX001

Click here to­ read full press release/ article 

 Ref: Vertex | Image: Vertex


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions